AVLN,MPLT Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AAPG ABEO SPTX ABCL ABSI AARD ABOS ABVX ACET IVA

| Held by: VTI IWM VXF VTWO IWO SCHA TMSL IWN VTWG SCHB

Index	RUT
Market Cap	1.23B
Enterprise Value	1.50B
Income	-
Sales	-
Book/sh	-5.96
Cash/sh	2.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	50
IPO	Apr 30, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	10.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.80
Current Ratio	10.80
Debt/Eq	0.15
LT Debt/Eq	0.15
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.31
EPS next Q	-0.74
EPS this Y	28.45%
EPS next Y	14.18%
EPS next 5Y	9.19%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 03 BMO
EPS/Sales Surpr.	-265.25% -

Insider Own	40.04%
Insider Trans	8.49%
Inst Own	5.70%
Inst Trans	81.22%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.79%
SMA50	-2.98%
SMA200	-3.18%
Trades

Shs Outstand	44.33M
Shs Float	26.58M
Short Float	8.24%
Short Ratio	4.51
Short Interest	2.19M
52W High	33.32 -16.60%
52W Low	24.15 15.07%
Volatility	6.57% 7.55%
ATR (14)	2.21
RSI (14)	46.56
Beta	-
Rel Volume	0.00
Avg Volume	486.17K
Volume	0

Perf Week	-4.27%
Perf Month	-9.51%
Perf Quarter	-
Perf Half Y	-
Perf YTD	6.88%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	59.00
Prev Close	27.79
Price	27.79
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Initiated	Morgan Stanley	Overweight	$53
May-26-26	Initiated	Jefferies	Buy	$52
May-26-26	Initiated	Guggenheim	Buy	$80
May-26-26	Initiated	Evercore ISI	Outperform	$51

Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jun-17-26 08:00AM	Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis (GlobeNewswire)
Jun-03-26 08:07AM	Avalyn: Q1 Earnings Snapshot (Associated Press)
07:00AM	Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-27-26 08:00AM	Avalyn to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
May-21-26 08:00AM	Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 (GlobeNewswire)
May-05-26 04:01PM	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference (GlobeNewswire) -5.64%
May-01-26 04:01PM	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

CEOMs. Lyn Baranowski

CFO & Chief Business OfficerMr. Douglas R. Carlson

Ph.D.Dr. Melissa Rhodes DABT

Chief Medical OfficerDr. Howard M. Lazarus M.D.

Senior Director of IR & Corporate CommunicationsMs. Cassie Saitow

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

MPLT MapLight Therapeutics Inc daily Stock Chart

Peers: ACAD AXSM KYMR NUVL BMRN RYTM INCY KRYS MDGL NBIX

| Held by: VTI VXF XBI IWM VTWO VHT SCHA IWO TMSL FESM

Index	RUT
Market Cap	528.47M
Enterprise Value	223.95M
Income	-199.48M
Sales	0.00M
Book/sh	8.84
Cash/sh	7.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	133
IPO	Oct 27, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.40
P/C	1.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	22.91
Current Ratio	22.91
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-4.52
EPS next Y	-4.14
EPS next Q	-1.33
EPS this Y	72.27%
EPS next Y	19.61%
EPS next 5Y	36.91%
EPS past 3/5Y	-71.59% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-148.89%
Sales Q/Q	-
Earnings	May 14 AMC
EPS/Sales Surpr.	-27.89% -

Insider Own	81.31%
Insider Trans	-2.51%
Inst Own	30.48%
Inst Trans	3.90%
ROA	-75.23%
ROE	-80.95%
ROIC	-49.31%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-62.70%
SMA50	-59.96%
SMA200	-45.62%
Trades

Shs Outstand	45.21M
Shs Float	7.97M
Short Float	45.00%
Short Ratio	5.75
Short Interest	3.59M
52W High	40.43 -69.33%
52W Low	9.10 36.26%
Volatility	20.10% 10.96%
ATR (14)	4.00
RSI (14)	25.24
Beta	-
Rel Volume	0.43
Avg Volume	623.33K
Volume	13,448

Perf Week	-64.88%
Perf Month	-63.85%
Perf Quarter	-59.09%
Perf Half Y	-35.25%
Perf YTD	-29.41%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.14
Target Price	32.31
Prev Close	12.31
Price	12.40
Change	0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21
Jul-21-26	Initiated	BMO Capital Markets	Outperform	$46
Jun-25-26	Initiated	Raymond James	Strong Buy	$46
May-27-26	Initiated	UBS	Buy	$48
May-21-26	Initiated	Craig Hallum	Buy	$43
May-04-26	Initiated	H.C. Wainwright	Buy	$45
Apr-08-26	Initiated	Needham	Buy	$37
Apr-07-26	Initiated	TD Cowen	Buy
Mar-19-26	Initiated	Canaccord Genuity	Buy	$35
Nov-21-25	Initiated	Stifel	Buy	$28
Nov-21-25	Initiated	Morgan Stanley	Overweight	$34
Nov-21-25	Initiated	Leerink Partners	Outperform	$30
Nov-21-25	Initiated	Jefferies	Buy	$32

Show Previous Ratings

Jul-28-26 11:06AM	MapLight Therapeutics stock crashes on Phase II schizophrenia data (Clinical Trials Arena) +24.28%
Jul-27-26 07:08PM	MPLT Stock Plunges 73% Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose (Stocktwits) -72.91%
07:00AM	MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia (GlobeNewswire)
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jun-24-26 07:00AM	MapLight Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +7.02%
07:00AM	Loading…
Jun-22-26 07:00AM	MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder (GlobeNewswire)
May-14-26 04:05PM	MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-08-26 07:00AM	MapLight Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.16%
May-01-26 07:00AM	MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results (GlobeNewswire)
Mar-26-26 07:00AM	MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.01%
Mar-02-26 07:00AM	MapLight Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:00AM	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 (GlobeNewswire)
Jan-05-26 07:00AM	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis (GlobeNewswire)
Dec-16-25 07:00AM	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies (GlobeNewswire)
Dec-04-25 07:00AM	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress (GlobeNewswire) +8.39%
07:26PM	Loading…
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

M.D.Dr. Christopher A. Kroeger M.B.A.

Ph.D.Dr. Robert C. Malenka M.D.

Ph.D.Dr. Erin Pennock Foff M.D.

FounderDr. Karoly Nikolich Ph.D.

Ph.D.Dr. Karl Deisseroth M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cox Troy	Director	Jul 28 '26	Buy	9.52	15,620	148,702	15,620	Jul 28 09:14 PM
GILLIS JONATHAN	CAO and Interim CFO	Jul 17 '26	Sale	37.60	18,469	694,463	144,240	Jul 20 06:00 AM
GILLIS JONATHAN	CAO and Interim CFO	Jul 15 '26	Sale	36.51	10,055	367,093	171,164	Jul 20 06:00 AM
GILLIS JONATHAN	CAO and Interim CFO	Jul 16 '26	Sale	36.80	8,455	311,112	162,709	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 17 '26	Sale	37.60	17,173	645,719	174,906	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 15 '26	Sale	36.49	10,055	366,940	201,135	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 16 '26	Sale	36.80	9,056	333,235	192,079	Jul 20 06:00 AM
Kroeger Christopher A.	Chief Executive Officer	Jul 16 '26	Sale	36.79	69,082	2,541,341	1,263,234	Jul 17 09:46 PM
Kroeger Christopher A.	Chief Executive Officer	Jul 15 '26	Sale	36.69	61,778	2,266,457	1,332,316	Jul 17 09:46 PM
Kroeger Christopher A.	Chief Executive Officer	Jul 17 '26	Sale	37.90	16,779	635,924	1,246,455	Jul 17 09:46 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 16 '26	Sale	36.79	8,547	314,412	226,539	Jul 17 09:45 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 15 '26	Sale	36.70	7,643	280,506	235,086	Jul 17 09:45 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 17 '26	Sale	37.90	2,077	78,718	224,462	Jul 17 09:45 PM
Hanson Kristopher	General Counsel	Jul 16 '26	Sale	36.78	8,118	298,616	146,953	Jul 17 09:44 PM
Hanson Kristopher	General Counsel	Jul 15 '26	Sale	36.70	7,260	266,427	155,071	Jul 17 09:44 PM
Hanson Kristopher	General Counsel	Jul 17 '26	Sale	37.90	1,130	42,827	145,823	Jul 17 09:44 PM
Foff Erin Pennock	Chief Medical Officer	Jul 15 '26	Sale	36.64	28,455	1,042,594	317,604	Jul 17 09:43 PM
Foff Erin Pennock	Chief Medical Officer	Jul 16 '26	Sale	36.77	15,047	553,334	302,557	Jul 17 09:43 PM
Foff Erin Pennock	Chief Medical Officer	Jul 17 '26	Sale	37.90	3,656	138,562	298,901	Jul 17 09:43 PM
ANATOL KREITZER	Officer	Jul 17 '26	Proposed Sale	37.22	17,173	639,179		Jul 17 04:21 PM
JONATHAN GILLIS	Officer	Jul 17 '26	Proposed Sale	37.22	18,469	687,416		Jul 17 04:21 PM
Jonathan Gillis	Officer	Jul 15 '26	Proposed Sale	37.91	36,979	1,401,874		Jul 15 07:59 PM
Anatol Kreitzer	Officer	Jul 15 '26	Proposed Sale	37.91	33,605	1,273,966		Jul 15 07:56 PM
Foff Erin Pennock	Officer	Jul 15 '26	Proposed Sale	37.91	48,158	1,825,670		Jul 15 04:44 PM
ROBERT MALENKA	Director	Jul 15 '26	Proposed Sale	37.91	17,537	664,828		Jul 15 04:23 PM
Kroeger Christopher A.	Officer	Jul 15 '26	Proposed Sale	37.91	152,230	5,771,039		Jul 15 04:17 PM
Hanson Kristopher	Officer	Jul 15 '26	Proposed Sale	37.91	16,508	625,818		Jul 15 04:11 PM
Lillie James Woodruff	Officer	Jul 15 '26	Proposed Sale	37.91	18,835	714,035		Jul 15 04:01 PM
Kroeger Christopher A.	Chief Executive Officer	May 18 '26	Sale	27.19	118,235	3,215,000	1,394,094	May 18 09:27 PM
Hanson Kristopher	General Counsel	May 11 '26	Sale	30.13	13,917	419,263	162,331	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 08 '26	Sale	27.69	34,411	952,835	1,526,309	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 07 '26	Sale	28.65	20,100	575,797	1,560,720	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 11 '26	Sale	30.11	13,980	421,002	1,512,329	May 11 09:30 PM
Foff Erin Pennock	Chief Medical Officer	May 07 '26	Sale	28.54	4,438	126,640	346,059	May 11 09:30 PM
Lillie James Woodruff	Chief Scientific Officer	May 07 '26	Sale	28.28	721	20,390	242,729	May 11 09:30 PM
Setia Vishwas	Chief Financial Officer	May 04 '26	Sale	28.11	14,904	418,930	377,723	May 06 08:15 PM
Setia Vishwas	Chief Financial Officer	May 05 '26	Sale	28.20	10,903	307,444	366,820	May 06 08:15 PM
Setia Vishwas	Chief Financial Officer	May 06 '26	Sale	28.24	10,564	298,345	356,256	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 06 '26	Sale	28.76	24,052	691,749	350,497	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 04 '26	Sale	27.96	15,652	437,629	385,125	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 05 '26	Sale	28.20	10,576	298,216	374,549	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 06 '26	Sale	28.76	24,811	713,599	243,450	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 04 '26	Sale	27.96	15,801	441,813	279,356	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 05 '26	Sale	28.20	11,095	312,839	268,261	May 06 08:15 PM
Hanson Kristopher	General Counsel	May 04 '26	Sale	27.89	13,917	388,177	176,248	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 06 '26	Sale	28.76	23,701	681,583	1,580,820	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 04 '26	Sale	27.96	15,571	435,363	1,614,993	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 05 '26	Sale	28.20	10,472	295,289	1,604,521	May 06 08:15 PM
Kroeger Christopher A.	Officer	May 04 '26	Proposed Sale	30.70	236,470	7,259,629		May 04 05:47 PM
Setia Vishwas	Officer	May 04 '26	Proposed Sale	30.70	36,371	1,116,590		May 04 05:28 PM
Foff Erin Pennock	Officer	May 04 '26	Proposed Sale	30.70	54,718	1,679,843		May 04 05:22 PM
Lillie James Woodruff	Officer	May 04 '26	Proposed Sale	30.70	52,428	1,609,540		May 04 05:20 PM
Hanson Kristopher	Officer	May 04 '26	Proposed Sale	30.70	27,834	854,504		May 04 05:18 PM
GILLIS JONATHAN	CAAO and PAO	Apr 27 '26	Sale	29.74	51,900	1,543,369	199,154	Apr 29 04:30 PM
GILLIS JONATHAN	CAAO and PAO	Apr 28 '26	Sale	30.35	17,935	544,319	181,219	Apr 29 04:30 PM
Kreitzer Anatol	Chief Discovery Officer	Apr 27 '26	Sale	29.66	45,422	1,347,066	211,190	Apr 29 04:30 PM
ANATOL KREITZER	Officer	Apr 27 '26	Proposed Sale	29.76	45,422	1,351,759		Apr 27 04:34 PM
JONATHAN GILLIS	Officer	Apr 27 '26	Proposed Sale	29.76	69,835	2,078,290		Apr 27 04:32 PM
Kreitzer Anatol	Chief Discovery Officer	Apr 15 '26	Sale	26.61	3,316	88,239	256,612	Apr 17 04:05 PM
GILLIS JONATHAN	CAAO and PAO	Apr 15 '26	Sale	26.61	3,590	95,530	251,054	Apr 17 04:05 PM
Hanson Kristopher	General Counsel	Apr 15 '26	Sale	26.80	1,529	40,977	190,463	Apr 17 04:05 PM
Hanson Kristopher	General Counsel	Apr 16 '26	Sale	27.37	298	8,157	190,165	Apr 17 04:05 PM
Setia Vishwas	Chief Financial Officer	Apr 15 '26	Sale	26.87	2,806	75,397	392,743	Apr 17 04:05 PM
Setia Vishwas	Chief Financial Officer	Apr 16 '26	Sale	27.37	116	3,175	392,627	Apr 17 04:05 PM
Lillie James Woodruff	Chief Scientific Officer	Apr 16 '26	Sale	27.37	2,783	76,175	295,157	Apr 17 04:05 PM
Lillie James Woodruff	Chief Scientific Officer	Apr 15 '26	Sale	26.82	1,730	46,399	297,940	Apr 17 04:05 PM
Foff Erin Pennock	Chief Medical Officer	Apr 15 '26	Sale	26.84	2,044	54,861	401,946	Apr 17 04:05 PM
Foff Erin Pennock	Chief Medical Officer	Apr 16 '26	Sale	27.37	1,169	31,998	400,777	Apr 17 04:05 PM
Kroeger Christopher A.	Chief Executive Officer	Apr 16 '26	Sale	27.37	10,052	275,141	1,630,564	Apr 17 04:05 PM
Kroeger Christopher A.	Chief Executive Officer	Apr 15 '26	Sale	26.93	9,135	246,006	1,640,616	Apr 17 04:05 PM
Malenka Robert C.	Director	Apr 15 '26	Sale	26.90	8,593	231,152	316,466	Apr 17 04:05 PM
Anatol Kreitzer	Officer	Apr 15 '26	Proposed Sale	27.02	5,000	135,100		Apr 15 05:20 PM
Jonathan Gillis	Officer	Apr 15 '26	Proposed Sale	27.02	4,000	108,080		Apr 15 05:15 PM
ROBERT MALENKA	Director	Apr 15 '26	Proposed Sale	27.02	8,593	232,183		Apr 15 04:47 PM
Kroeger Christopher A.	Officer	Apr 15 '26	Proposed Sale	27.02	20,822	562,610		Apr 15 04:28 PM
Setia Vishwas	Officer	Apr 15 '26	Proposed Sale	27.02	2,990	80,799		Apr 15 04:17 PM
Lillie James Woodruff	Officer	Apr 15 '26	Proposed Sale	27.02	4,896	132,290		Apr 15 04:14 PM
Hanson Kristopher	Officer	Apr 15 '26	Proposed Sale	27.02	1,827	49,366		Apr 15 04:11 PM
Foff Erin Pennock	Officer	Apr 15 '26	Proposed Sale	27.02	3,472	93,813		Apr 15 04:06 PM
Malenka Robert C.	Director	Feb 23 '26	Sale	18.42	11,264	207,464	325,795	Feb 24 06:57 PM
Malenka Robert C.	Director	Feb 20 '26	Sale	18.03	2,195	39,576	337,059	Feb 24 06:57 PM
Malenka Robert C.	Director	Feb 24 '26	Sale	18.15	736	13,358	325,059	Feb 24 06:57 PM
ROBERT MALENKA	Director	Feb 24 '26	Proposed Sale	18.14	736	13,355		Feb 24 04:36 PM
ROBERT MALENKA	Director	Feb 23 '26	Proposed Sale	18.42	11,264	207,491		Feb 23 04:33 PM
Pavlov George	Director	Feb 18 '26	Buy	17.48	10,658	186,302	10,658	Feb 20 06:25 PM
Pavlov George	Director	Feb 20 '26	Buy	17.86	9,920	177,171	25,000	Feb 20 06:25 PM
Pavlov George	Director	Feb 19 '26	Buy	17.57	4,422	77,695	15,080	Feb 20 06:25 PM
ROBERT MALENKA	Director	Feb 20 '26	Proposed Sale	18.03	2,195	39,577		Feb 20 04:16 PM
Malenka Robert C.	Director	Feb 13 '26	Sale	18.21	12,116	220,632	339,254	Feb 18 07:33 PM
ROBERT MALENKA	Director	Feb 13 '26	Proposed Sale	18.21	12,116	220,686		Feb 13 04:08 PM
Garnett Timothy John	Director	Feb 10 '26	Buy	17.89	14,124	252,678	14,124	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 10 '26	Sale	18.12	6,622	119,991	351,611	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 11 '26	Sale	18.00	241	4,338	351,370	Feb 12 05:45 PM
ROBERT MALENKA	Director	Feb 11 '26	Proposed Sale	18.00	241	4,338		Feb 11 04:13 PM
ROBERT MALENKA	Director	Feb 10 '26	Proposed Sale	18.12	6,622	119,963		Feb 10 04:22 PM
Malenka Robert C.	Director	Feb 02 '26	Sale	18.02	7,039	126,843	358,234	Feb 04 09:15 PM
Malenka Robert C.	Director	Feb 03 '26	Sale	18.00	1	18	358,233	Feb 04 09:15 PM
ROBERT MALENKA	Director	Feb 03 '26	Proposed Sale	18.00	1	18		Feb 03 04:15 PM
ROBERT MALENKA	Director	Feb 02 '26	Proposed Sale	18.02	7,039	126,835		Feb 02 04:37 PM
Malenka Robert C.	Director	Jan 29 '26	Sale	18.55	21,262	394,410	371,885	Jan 30 08:50 PM

AVLN

Avalyn Pharma Inc

MPLT

MapLight Therapeutics Inc

Upgrade your Finviz experience